CellProthera | Pionnier de la Thérapie Régénératrice Cardiaque

| 14 MAY 2024 - CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction - at the Late Breaking Clinical Trial Session of the European Society of Cardiology - Heart Failure Congress in Lisbon, Portugal | European Society of Cardiology – London, UK – August 30- September 2 | Join us at ISCT EUROPE GOTHENBURG September 04-06, Dr Ibon GARITAONANDIA presenting at 9:15 - 10:15 CEST on September 04, 2024

Autologous cell therapy for body regeneration

Personalised medicine based on the patients' own stem cells

Science & Technology

Adult stem cells are a natural source of cells in the body capable of regenerating multiple tissues. Our cellular product, ProtheraCytes®, which are expanded CD34+ cells, together with our technology has shown promising clinical results in the regeneration of cardiac tissues.
...

Therapy

A severe heart attack can lead to chronic heart failure that weakens heart function and reduces life expectancy. Current approved treatments mainly address symptoms but do not regenerate the damaged heart, therefore there is a high unmet need for alternative treatments. Regenerative Medicine emerges as a new breakthrough model of medicine that provides a therapeutic solution to regenerate both structurally and functionally the damaged organ.

CellProthera has followed up the patients treated in its pilot study for more than 15 years, and has shown survival and improvement of these patients. No other existing treatment whether it is stent, bypass or other drugs has shown such results.

Reference: Pasquet S, et al., Long-term benefit of intracardiac delivery of autologous granulocyte-colony-stimulating factor-mobilized blood CD34+ cells containing cardiac progenitors on regional heart structure and function after myocardial infarct. Cytotherapy. 2009;11(8):1002-15. ...

Our Story

In 2002, a successful Proof of Concept clinical study led by Pr Philippe HENON – Founder and Director of IRHT Mulhouse - showing structural and functional regeneration of myocardial tissue as well as reperfusion of an infarcted zone after a recent Acute Myocardial Infarct (AMI) was performed and included 7 myocardial infarction patients with a very poor short-term prognosis. Based on the objective of building a robust and automated bioprocessing technology aimed at producing large numbers of purified stem cells, CellProthera has developed a proprietary technology platform made of an automated expansion device called StemXpand® and its disposable kit StemPack®. The final cell product ProtheraCytes® is made of CD34+ stem cells which have the potential for regeneration of various damaged tissues. ProtheraCytes® is registered as an ATMP – Advanced Therapy Medicinal Product – within the classification of Tissue Engineered product by the European Medicines Agency. Our most advanced program is the regeneration of damaged heart tissue after severe AMI to prevent Heart Failure (HF). It is an unmet medical need suffered by over a million patients per year in the US, Europe and Japan. ...